Drug Trial News

RSS

No link between daily multivitamin use and reduction of major cardiovascular events in men

In a randomized study that included nearly 15,000 male physicians who were middle-aged or older, daily multivitamin use for more than 10 years of treatment and follow-up did not result in a reduction of major cardiovascular events, heart attack, stroke, or death from cardiovascular disease, according to a study appearing in November 7 issue of JAMA, a theme issue on cardiovascular disease.

5 Nov 2012

Endo, Bioniche decide to end second Urocidin Phase III trial on non-muscle-invasive bladder cancer

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced that a second Phase III clinical trial with Urocidin in non-muscle-invasive bladder cancer is being discontinued.

5 Nov 2012

AcelRx commences dosing in ARX-04 sufentanil NanoTab Phase 2 study for acute and breakthrough pain

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it has dosed the first subjects in a Phase 2, placebo-controlled, dose-finding study of its ARX-04 sufentanil NanoTab product candidate.

5 Nov 2012

PsiOxus receives UK government grant to initiate ColoAd1 Phase I/II trial for ovarian cancer

PsiOxus Therapeutics, Ltd., a development stage biotechnology company, today announced the award of a £1.7 million ($2.7 million) grant from the UK government-backed Biomedical Catalyst to initiate a Phase I/II clinical trial to assess the use of ColoAd1 in the treatment of platinum-resistant, recurrent ovarian cancer.

5 Nov 2012

Pradaxa use does not appear to increase serious bleeding

The U.S. Food and Drug Administration (FDA) today announced the results of a Mini-Sentinel assessment that indicates bleeding rates associated with new use of Pradaxa (dabigatran etexilate mesylate) capsules do not appear to be higher than bleeding rates associated with new use of warfarin, which is consistent with observations from the pivotal RE-LY trial.

4 Nov 2012

Blog reports on meeting of world's largest HIV vaccine research network

KPLU 88.5's "Humanosphere" blog reports on a meeting of the HIV Vaccine Trials Network (HVTN), "the world's largest HIV vaccine research network," held in Seattle this week. "We actually don't know what the agenda is," HVTN Executive Director Jim Kublin said during a lecture, titled "Scientific Agenda, the Next Seven Years," according to the blog.

3 Nov 2012

Isis Pharmaceuticals to receive $1.25M from Pfizer for continued advancement of EXC 001

Isis Pharmaceuticals, Inc. announced today that it will receive a $1.25 million contingent payment from Pfizer Inc. triggered by Pfizer's decision to advance EXC 001 into a Phase 2 study.

3 Nov 2012

Data from four Phase 2 trials of AMG 145 to be presented at AHA Scientific Sessions 2012

Amgen will present data from four Phase 2 trials of AMG 145, an investigational fully human monoclonal antibody directed against PCSK9, a protein that reduces the liver's ability to remove low density lipoprotein cholesterol, or "bad" cholesterol from the blood, at the upcoming American Heart Association Scientific Sessions 2012.

3 Nov 2012

Bristol-Myers Squibb, Pfizer and Portola partner to conduct clinical study of PRT4445 and ELIQUIS

Portola Pharmaceuticals, Inc., Bristol-Myers Squibb Company and Pfizer Inc. today announced a clinical collaboration agreement to conduct a proof-of-concept study of PRT4445 and the investigational oral Factor Xa inhibitor ELIQUIS (apixaban).

3 Nov 2012

Pfizer, Bristol-Myers Squibb announce data from ELIQUIS clinical trial on AF

Bristol-Myers Squibb Company and Pfizer Inc. today announced that a large number of data presentations sponsored by the companies on ELIQUIS (apixaban) and the treatment of atrial fibrillation will be presented at the American Heart Association 2012 Scientific Sessions, November 3-7, 2012, in Los Angeles, California.

3 Nov 2012

Lomitapide shows promise in treating homozygous familial hypercholesterolemia

An international effort led by researchers at the Perelman School of Medicine at the University of Pennsylvania has resulted in positive phase 3 clinical trial results for a new medicine to treat patients suffering from a rare and deadly cholesterol disorder.

3 Nov 2012

Tolvaptan shows promise in treating autosomal dominant polycystic kidney disease

A drug therapy shows promise for treating an inherited form of kidney disease called autosomal dominant polycystic kidney disease (ADPKD), Mayo Clinic researchers say.

3 Nov 2012

Top-line results from Aerie Pharmaceuticals' AR-13324 Phase 2a study on glaucoma

Aerie Pharmaceuticals, a biotechnology company focused on the discovery and development of novel treatments for glaucoma, today announced positive top-line results from its Phase 2a study evaluating AR-13324 for the treatment of glaucoma.

3 Nov 2012

Genkyotex announces positive results from GKT137831 Phase I studies on healthy subjects

Genkyotex, the leading developer of NOX inhibitors to treat oxygen-radical mediated diseases, announced today that Phase I studies have demonstrated excellent safety and tolerability following single and multiple oral doses of GKT137831, the first in class NOX 1 and 4 inhibitor. In addition, GKT137831 demonstrated a favourable pharmacokinetic profile in these subjects.

3 Nov 2012

Intensified antibiotic treatment can improve prognosis of patients with TB meningitis

Researchers from the Radboud UMC have conducted the first study globally to show that intensified antibiotic treatment can improve the prognosis of patients with tuberculous (TB) meningitis, the most severe form of TB which carries a mortality of up to 50%.

3 Nov 2012

Phase II study to evaluate Medivir/Janssen's simeprevir and Vertex against HCV

Medivir AB, announced today plans for a phase II proof-of-concept study of an all-oral regimen for the treatment of hepatitis C containing of Medivir/Janssen's protease inhibitor simeprevir and Vertex's nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor VX-135.

3 Nov 2012

Advanced breast cancer that has spread to the brain could be treated with drug combination

The sizeable and increasing proportion of women with advanced breast cancer whose disease has spread to the brain could be effectively treated systemically with a combination of two drugs, sparing them the debilitating neurological side effects of whole brain radiotherapy (WBRT), suggests new research published Online First in The Lancet Oncology.

2 Nov 2012

Virginia G. Piper, TESARO announce initiation of TSR-011 clinical trial for advanced cancer

TESARO, Inc. announced today that the first clinical trial of its proprietary Anaplastic Lymphoma Kinase (ALK) inhibitor, TSR-011, has commenced with the dosing of the first patient at the Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen).

2 Nov 2012

Imatinib mesylate effectively treats children with neurofibromatosis type 1 tumors

Physician-researchers at Indiana University School of Medicine have reported the first effective therapy for a class of previously untreatable and potentially life-threatening tumors often found in children.

2 Nov 2012

Link between ChemoFx Drug Response Marker results and RFS of cervical cancer patients

A new study reporting an association between ChemoFx Drug Response Marker results and recurrence free survival (RFS) of cervical cancer patients was presented at the 14th Biennial Meeting of the International Gynecologic Cancer Society (IGCS), held in Vancouver October 13-16, 2012.

2 Nov 2012

Drug Trial News

No link between daily multivitamin use and reduction of major cardiovascular events in men

Endo, Bioniche decide to end second Urocidin Phase III trial on non-muscle-invasive bladder cancer

AcelRx commences dosing in ARX-04 sufentanil NanoTab Phase 2 study for acute and breakthrough pain

PsiOxus receives UK government grant to initiate ColoAd1 Phase I/II trial for ovarian cancer

Pradaxa use does not appear to increase serious bleeding

Blog reports on meeting of world's largest HIV vaccine research network

Isis Pharmaceuticals to receive $1.25M from Pfizer for continued advancement of EXC 001

Data from four Phase 2 trials of AMG 145 to be presented at AHA Scientific Sessions 2012

Bristol-Myers Squibb, Pfizer and Portola partner to conduct clinical study of PRT4445 and ELIQUIS

Pfizer, Bristol-Myers Squibb announce data from ELIQUIS clinical trial on AF

Lomitapide shows promise in treating homozygous familial hypercholesterolemia

Tolvaptan shows promise in treating autosomal dominant polycystic kidney disease

Top-line results from Aerie Pharmaceuticals' AR-13324 Phase 2a study on glaucoma

Genkyotex announces positive results from GKT137831 Phase I studies on healthy subjects

Intensified antibiotic treatment can improve prognosis of patients with TB meningitis

Phase II study to evaluate Medivir/Janssen's simeprevir and Vertex against HCV

Advanced breast cancer that has spread to the brain could be treated with drug combination

Virginia G. Piper, TESARO announce initiation of TSR-011 clinical trial for advanced cancer

Imatinib mesylate effectively treats children with neurofibromatosis type 1 tumors

Link between ChemoFx Drug Response Marker results and RFS of cervical cancer patients

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News